Dialybrid S.r.l. raised €15 million (US$17 million) in a series A funding round for its Silkothane Arteriovenous Graft, a ...

Epidermal growth factor receptor (EGFR) is a well-known validated target for the development of EGFR-mutant lung cancer ...

Novartis Pharma AG inked a potential $900 million deal to gain exclusive global rights to a preclinical radioligand therapy ...

SK Biopharmaceuticals Co. Ltd. signed a licensing and equity deal agreement to acquire global rights to 1ST-104, a preclinical type II LRRK2/c-Abl tyrosine kinase inhibitor, for Parkinson’s disease ...

Biopharma and med-tech companies raising money in public or private financings, including: Aethlon, Aitiologic, Avava, Beta Bionics, Betterlife, Big Picture, Biodexa, Calida, Cambium, Cardiol, Circio, ...

CD47 is a protein leading to immunosuppression in lung cancer, allowing cancer cells to escape the immune system by transmitting a “do not eat me” signal, thus inhibiting phagocytosis. CD47 blockade ...

Telix Pharmaceuticals Ltd. has agreed to acquire ITM Isotope Technologies Munich SE for up to $2.35 billion, seeking greater ...

Two years after the U.S. FDA approval of Aqneursa (levacetylleucine) in Niemann-Pick disease type C, Intrabio Inc.’s ...

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Positive allosteric modulators (PAMs) of muscarinic acetylcholine M1 receptor are being developed to address cognitive deficits in Alzheimer’s disease, schizophrenia and other neuropsychiatric ...

Monocytic acute myeloid leukemia (AML), including French-American-British (FAB) M4 and M5 subtypes, is an aggressive malignancy that frequently involves extramedullary tissues and often responds ...

Kymera Therapeutics Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 ...